VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

The efficacy of a third dose of the COVID-19 vaccine in HCT, CAR-T and BiTE recipients

In this video, Muhammad Bilal Abid, MD, MRCP, Medical College of Wisconsin, Milwaukee, WI, discusses the results from a study which investigated the efficacy of administering a third dose of the COVID-19 mRNA vaccine to recipients of hematopoietic cell transplantation (HCT), chimeric antigen receptor T-cell (CAR-T), and bispecific T-cell engager therapies (BiTEs). Although these patients had not seroconverted after the first two doses of the vaccine, 59% of patients in this study developed protective antibodies following the third dose. Dr Abid further discusses the results of this study, including the antibody titers in myeloma patients versus lymphoma patients, and the seroconversion rates in myeloma BiTE recipients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter